undamentalytics Newsletter

Heyburn William A.: insider trades

Chief executive, Chief financial officer at Strata Critical Medical, Inc. 1 open-market purchase and 9 sales not made under a pre-set plan, reported from October 11, 2022 to June 10, 2026.

Would copying Heyburn William A.’s purchases have beaten the S&P 500?

Too few purchases to judge. None of their purchases has 12 months of prices after the report; we judge insiders once they have 20. The figures below can swing a long way on a handful of trades. Buying each purchase the day after it was reported, an equal amount each, and holding it 12 months or until they reported a sale would have turned $10,000 on December 11, 2025 into $10,602 by November 2, 2026, +6.8% a year. The copy held shares only 56% of the time, so the fair comparison is the S&P 500 on those same days with Treasury bills otherwise: $10,936, +10.6% a year (the S&P 500 held throughout made $11,095, +12.5% a year). Beta against the index was 1.23.

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

$0$5.0k$10.0k 20252026 $11.1k$10.9k$10.6k
Copying Heyburn William A.S&P 500, same days investedS&P 500, held throughout $10,000 copying Heyburn William A.’s open-market purchases from December 11, 2025, before costs and taxes, marked weekly. Each purchase gets the same starting stake, bought at the close of the first trading day after the report and sold 12 months later or the day after a reported sale of that stock; uninvested money earns the Treasury bill rate. “Same days invested” holds the S&P 500 only on the days the copy held shares, Treasury bills otherwise.
Return a year, copying
+6.8%
S&P 500, same days invested
+10.6% (held throughout +12.5%)
Time in shares
56%
Sharpe ratio (S&P 500)
0.27 (0.68)
Biggest drop (S&P 500)
−32% (−9%)
Market sensitivity (beta)
1.23
Purchases copied
1

Trade by trade

Heyburn William A.: trades against the S&P 500 afterwards
MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 1 −10.9% −10.9% 0% 1 — — Not enough years
Purchases, 6 months after the report 1 +1.8% +1.8% 100% 1 — — Not enough years
Purchases, 12 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the trade 0 — — — — — — Not enough years
Sales, 3 months after the report 1 −9.2% −9.2% 100% 1 — — Not enough years
Sales, 12 months after the report 0 — — — — — — Not enough years
Sales, 12 months after the trade 0 — — — — — — Not enough years

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
Strata Critical Medical, Inc. SRTA Co-CEO and CFO19October 11, 2022June 10, 2026

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
June 10, 2026June 8, 2026 SRTA Sale $185,909 −9.2%not yetnot yet
December 10, 2025December 9, 2025 SRTA Purchase $75,990 −10.9%not yetnot yet
April 5, 2024April 3, 2024 SRTA Sale $67,411 not yetnot yetnot yet
March 15, 2024March 13, 2024 SRTA Sale $144,875 not yetnot yetnot yet
December 15, 2023December 13, 2023 SRTA Sale $116,106 not yetnot yetnot yet
October 6, 2023October 4, 2023 SRTA Sale $95,493 not yetnot yetnot yet
July 10, 2023July 6, 2023 SRTA Sale $320,275 not yetnot yetnot yet
April 11, 2023April 5, 2023 SRTA Sale $120,251 not yetnot yetnot yet
January 12, 2023January 9, 2023 SRTA Sale $14,942 not yetnot yetnot yet
October 11, 2022October 6, 2022 SRTA Sale $14,864 not yetnot yetnot yet

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why Heyburn William A. traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.